F Wang1, L Zhou1, X Ma1, W Ma2, C Wang1, Y Lu1, Y Chen1, L An1, W An3, Y Yang4. 1. Center of Therapeutic Research for Hepatocellular Carcinoma, Beijing the 302(nd) Hospital, Beijing, China. 2. Department of Radiology, Beijing the 302(nd) Hospital, Beijing, China. 3. Department of Magnetic Resonance Imaging (MRI), Beijing the 302(nd) Hospital, Beijing, China. 4. Center of Therapeutic Research for Hepatocellular Carcinoma, Beijing the 302(nd) Hospital, Beijing, China. Electronic address: yongpingyang@hotmail.com.
Abstract
BACKGROUND: Acute-on-chronic liver failure (ACLF) is defined as an acute deterioration of chronic liver disease. Intrasplenic hepatocyte transplantation is increasingly recognized as a treatment for liver failure and genetic metabolic liver diseases. We describe our experience of intrasplenic hepatocyte transplantation in a small cohort of patients as bridge therapy or as an alternative to orthotopic liver transplantation (OLT). METHODS: Seven patients with ACLF with an expected survival of less than 8 weeks were enrolled into the study. The donor hepatocytes were collected from 2 healthy males and cryopreserved. Donor hepatocytes were transplanted into the spleen of recipients via catheterization of the femoral artery. All patients were followed up for 5 years or to death. RESULTS: A total of (4.2-6.0) × 10(10) hepatocytes were harvested from the 2 donors' livers and their survival after recovery from the frozen stock was 63% ± 2.8% and 73.5% ± 3.2%, respectively. Following intrasplenic hepatocyte transplantation, 3 patients fully recovered from liver failure, 1 survived and subsequently underwent OLT, and the remaining 3 patients died between 2.5 and 12 months after intrasplenic hepatocyte transplantation. At month 48 post-intrasplenic hepatocyte transplantation, living hepatocyte signals were observed in the spleen using magnetic resonance imaging (MRI) with gadobenate dimeglumine (Gd-BOPTA). CONCLUSIONS: Intrasplenic hepatocyte transplantation is a promising therapy for liver failure that may reduce mortality rates among patients with end-stage liver disease awaiting OLT. Conceivably, intrasplenic hepatocyte transplantation may be considered an alternative to OLT for patients with acute liver failure. MRI (Gd-BOPTA) is a useful tool for detecting living hepatocytes in the spleen after intrasplenic hepatocyte transplantation.
BACKGROUND: Acute-on-chronic liver failure (ACLF) is defined as an acute deterioration of chronic liver disease. Intrasplenic hepatocyte transplantation is increasingly recognized as a treatment for liver failure and genetic metabolic liver diseases. We describe our experience of intrasplenic hepatocyte transplantation in a small cohort of patients as bridge therapy or as an alternative to orthotopic liver transplantation (OLT). METHODS: Seven patients with ACLF with an expected survival of less than 8 weeks were enrolled into the study. The donor hepatocytes were collected from 2 healthy males and cryopreserved. Donor hepatocytes were transplanted into the spleen of recipients via catheterization of the femoral artery. All patients were followed up for 5 years or to death. RESULTS: A total of (4.2-6.0) × 10(10) hepatocytes were harvested from the 2 donors' livers and their survival after recovery from the frozen stock was 63% ± 2.8% and 73.5% ± 3.2%, respectively. Following intrasplenic hepatocyte transplantation, 3 patients fully recovered from liver failure, 1 survived and subsequently underwent OLT, and the remaining 3 patients died between 2.5 and 12 months after intrasplenic hepatocyte transplantation. At month 48 post-intrasplenic hepatocyte transplantation, living hepatocyte signals were observed in the spleen using magnetic resonance imaging (MRI) with gadobenate dimeglumine (Gd-BOPTA). CONCLUSIONS: Intrasplenic hepatocyte transplantation is a promising therapy for liver failure that may reduce mortality rates among patients with end-stage liver disease awaiting OLT. Conceivably, intrasplenic hepatocyte transplantation may be considered an alternative to OLT for patients with acute liver failure. MRI (Gd-BOPTA) is a useful tool for detecting living hepatocytes in the spleen after intrasplenic hepatocyte transplantation.
Authors: Jan Best; Paul Manka; Wing-Kin Syn; Laurent Dollé; Leo A van Grunsven; Ali Canbay Journal: Hepatobiliary Surg Nutr Date: 2015-02 Impact factor: 7.293
Authors: Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742
Authors: Chaoqun Hu; Yun He; Shuyu Fang; Na Tian; Mengjia Gong; Xiaohui Xu; Li Zhao; Yi Wang; Tongchuan He; Yuanyuan Zhang; Yang Bi Journal: Am J Transl Res Date: 2020-09-15 Impact factor: 4.060
Authors: Jason M Zimmerer; Phillip H Horne; Mason G Fisher; Thomas A Pham; Keri E Lunsford; Bryce A Ringwald; Christina L Avila; Ginny L Bumgardner Journal: Transplantation Date: 2016-09 Impact factor: 4.939
Authors: Ramon E Coronado; Maria Somaraki-Cormier; Shanmugasundaram Natesan; Robert J Christy; Joo L Ong; Glenn A Halff Journal: Cell Transplant Date: 2017-12 Impact factor: 4.064